{"brief_title": "A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium", "brief_summary": "Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.", "condition": ["Urologic Neoplasms", "Metastases, Neoplasm"], "intervention_type": ["Drug"], "intervention_name": ["pemetrexed"], "criteria": "Inclusion Criteria: - You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body. - You must have at least one tumor that can be physically measured or scanned by x-ray. - You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago. Exclusion Criteria: - You may not have used an experimental medicine or device within the past month. - Cancer that has spread to your brain. - If you are unwilling or unable to take folic acid or vitamin B12 supplements.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Transitional cell carcinoma of the urothelium", "mesh_term": ["Neoplasms", "Carcinoma, Transitional Cell", "Urologic Neoplasms", "Neoplasm Metastasis", "Pemetrexed"], "id": "NCT00035061"}